Paxabel

Quick links to important sections

Paxabel

Method of action: Laxative

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Paxabel

Quick Facts

Property Description
Active ingredient Macrogol 4000 (Polyethylene glycol 4000)
Form Powder for oral solution
Pharmacological class Osmotic Laxative (ATC code A06AD15)
Common use Symptomatic treatment of constipation
Origin Synthetic polymer

What Type of Medicine Is Paxabel and What Is Its Core Function?

Paxabel is classified as an osmotic laxative, a specific pharmacological class of medicine utilized for the symptomatic relief of conditions characterized by difficult or infrequent bowel movements. Its identity is defined by the sole active ingredient, Macrogol 4000, which is the International Nonproprietary Name (INN) for Polyethylene glycol 4000. This active compound is widely clinically recognized as a highly effective non-stimulant agent for managing constipation, with its classification placing it within the ATC code A06AD15. The general function of Paxabel is to effectively facilitate a more natural and comfortable passage of stool, directly addressing the difficulty associated with hardened intestinal contents. Unlike stimulant laxatives, the drug’s mechanism of effect is fundamentally different, operating through a physically inert process that avoids direct nerve stimulation in the intestine.

Composition and Pharmaceutical Preparation of Paxabel

The composition of Paxabel is based on a single-ingredient product formulation featuring Macrogol 4000. This key substance is a synthetic polymer provided in the high-level dosage form of a fine powder for oral solution, intended for oral administration. The formulation’s effectiveness depends on the powder being fully dissolved in an aqueous medium before consumption. The Macrogol 4000 is not absorbed into the systemic circulation and is metabolically inert, ensuring the compound remains localized in the large intestine. This action allows the Macrogol 4000 to maximize its water-binding capacity within the lumen, which leads to a critical modification of the stool's volume and fluid content, promoting easier, more natural colonic transit.

What side effects are possible with Paxabel?

Possible Side Effects and Safety Information

The safety profile of Paxabel (macrogol 4000) is primarily characterized by effects on the gastrointestinal system, which are generally mild and temporary. Frequencies of reported reactions are based on clinical studies and post-marketing surveillance.

Classification Frequency Adverse Reactions
Gastrointestinal Common Abdominal pain, abdominal distension, diarrhea, nausea.
Uncommon Vomiting, urgency to defecate, fecal incontinence (in adults).
Immune System Very Rare/Not Known Hypersensitivity reactions (e.g., rash, urticaria, angioedema), and exceptional cases of anaphylactic shock.

Serious Adverse Reactions and Safety Precautions

While most effects are minor, very rare cases of severe hypersensitivity reactions have been documented in association with macrogol 4000-containing products, including anaphylactic shock. Excessive dosage can lead to diarrhea, which, if prolonged or severe, may cause electrolyte disturbances and dehydration, particularly in susceptible patients.

Contraindications define situations where this medicine must not be used. These include severe organic inflammatory diseases of the colon (such as Crohn's disease or ulcerative colitis), toxic megacolon, intestinal perforation or a risk of perforation, intestinal obstruction (ileus), and hypersensitivity to the active substance or excipients. Individuals with hereditary fructose intolerance should also avoid this product.

Special monitoring is required for patients predisposed to fluid and electrolyte imbalance, such as those with impaired kidney or liver function or individuals taking diuretics. In children, official documents state that treatment should not exceed three months due to a lack of clinical data for longer durations.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Paxabel

The officially documented manifestations of a Paxabel (Macrogol 4000) overdose are primarily an exaggeration of the osmotic effect.

Overdose presents with symptoms such as diarrhea, abdominal pain, vomiting, and abdominal distension. These symptoms usually resolve upon temporary suspension of treatment or a reduction of the dosage, followed by a resumption of treatment at a lower level.


Documented Severe Outcomes and Required Actions

The principal severe outcome linked to overdose is excessive fluid loss and resulting electrolyte disturbances, including hyponatremia and hypokalaemia. The regulatory guidance mandates that management requires symptomatic and supportive treatment and the correction of electrolyte disturbances if they occur. Monitoring of the patient's electrolyte status is necessary for those with severe diarrhea or pre-existing imbalances. No specific antidote is available.

Population-specific considerations exist, noting that elderly patients are at an increased risk of dehydration and subsequent electrolyte disorders. Additionally, immediate medical help is explicitly required if signs of severe hypersensitivity reactions (e.g., Anaphylactic Shock, Angioedema) occur.

Therapeutic Uses of Paxabel

What Paxabel Treats: Main Uses and Benefits

Paxabel (Macrogol 4000) is a commonly used therapy primarily used for the symptomatic treatment of constipation in both adults and children. Macrogol is generally indicated for managing conditions involving recurrent or persistent bowel irregularity.


Treatment of Functional Symptoms

The medication is commonly used across conditions presenting with episodic or fluctuating symptom patterns, particularly chronic functional constipation. It is relevant in clinical settings marked by the core symptoms of infrequent bowel movements and the feeling of incomplete evacuation, and is also applied in addressing pronounced symptoms related to the physical difficulty of elimination, specifically straining on the toilet and the presence of hard, dry stools.

This supportive therapeutic benefit helps patients cope more steadily with chronic manifestations and may assist with maintaining functional stability. It is relevant in areas where symptomatic support is needed, such as conditions involving recurrent manifestations or temporary, acute episodes, including for older adults and children.

“The primary benefit is in providing supportive symptomatic assistance to manage physical symptoms and contributes to easing discomfort.”


Supportive Management for Key Patient Groups

The use of this osmotic laxative is considered relevant for managing constipation in vulnerable groups, including the pediatric population and older adults. It provides supportive symptomatic assistance that helps address groups of symptoms that interfere with daily comfort, offering supportive relief when symptoms interfere with routine activities.


Quick Fact: Summary: Support for Physical Symptoms

Property Description
Symptom focus Hard stools, straining, infrequent bowel movements
Use context Chronic functional management, acute episodes
Core benefit Easing overall symptom load, supporting functional stability

Regulatory References

  1. NIH StatPearls overview of Polyethylene Glycol

Eligibility and Restrictions for Use

Eligibility and Contraindications

Paxabel (Macrogol 4000) is authorized for use in adults and children aged 8 years and above. Use in children under 8 years requires specific medical assessment, and treatment duration for all children must not exceed 3 months due to lack of longer-term data.

Population Status Eligibility Rule (Official Labeling)
Contraindicated Patients with known hypersensitivity to Macrogol or a severe inflammatory bowel disease (e.g., Crohn's disease, Ulcerative Colitis) [Source 3.1]. Also excluded are individuals with intestinal obstruction, gastrointestinal perforation or risk of perforation, toxic megacolon, or abdominal pain of undetermined cause [Source 3.1].
Conditional Use Elderly patients, and those with impaired renal or hepatic function or taking diuretics, must exercise caution due to the risk of fluid and electrolyte imbalances [Source 2.1].
Pregnancy/Lactation Permitted for use during pregnancy and breastfeeding, as systemic absorption of the active ingredient is negligible [Source 3.1].

Eligibility is also affected by excipients: patients with hereditary fructose intolerance must not use certain formulations [Source 3.1].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Paxabel (Macrogol 3350) is minimally absorbed into the bloodstream, which generally means it has a low risk of conventional drug-drug interactions mediated by metabolic enzymes like CYP450 or drug transporters. The documented interactions are primarily physical or pharmacodynamic.

Potential Interaction Mechanisms

Interaction Type Practical Implication
Physical Interference with Absorption Due to increased gastrointestinal transit time, the absorption of other orally administered medicines may be transiently reduced.
Pharmacodynamic Interference Macrogol 3350 may liquefy products thickened with starch-based food thickeners, making the thickened liquid unsafe for consumption by patients with swallowing difficulties.
Secondary Electrolyte Risk The osmotic action carries a secondary risk of fluid/electrolyte disturbances, requiring caution when used concurrently with medications such as Diuretics, ACE Inhibitors, ARBs, or NSAIDs.

Official Constraints

To minimize the risk of reduced absorption of other oral medicines, official labeling advises a timing separation. It is recommended that other oral medicines not be taken for one hour before, during, and one hour after the administration of Paxabel. No medicines are specifically listed as strictly contraindicated with Paxabel based on a drug-drug interaction mechanism.

Mechanism of Action

Paxabel's mechanism of action, derived from its active ingredient Macrogol 4000, is strictly physico-chemical and locally confined to the intestinal lumen, operating independently of cellular receptors or enzyme systems. The Macrogol 4000 polymer binds water molecules via hydrogen bonds in the colon. This binding creates a local osmotic gradient, which functions to prevent the natural reabsorption of fluid across the colonic wall, ensuring the fecal mass remains highly hydrated.

This sequestration of fluid directly leads to an increase in the volume and a softening of the consistency of the stool. This bulked-up, softer mass mechanically distends the colonic wall, which serves as a natural, physiological stimulus to activate peristalsis—the propulsive contractions of the smooth muscle. This indirect modulation results in acceleration of intestinal transit.

The mechanism is entirely reliant on the presence of an aqueous medium and cannot be effective in the absence of sufficient fluid for dissolution. Furthermore, the osmotic action is strictly peripheral and mechanical, meaning it has limitations when faced with organic obstructions or severe underlying pathology that physically constrain the movement of luminal contents.

Dosage and Administration Information

Official Administration Guidelines

Paxabel (Macrogol 4000) is officially approved for oral use only, administered as a reconstituted solution. The primary instruction requires that the powder contents of the sachet must be fully dissolved in water just before consumption, establishing the mandatory preparation step for administration. A 10 g sachet is typically diluted in approximately 125 ml (a glass) of water, while the 4 g sachet uses approximately 50 ml of water.


Dosing Schedule and Frequency

The standard adult dosing range is one to two sachets (10 g to 20 g) per day. The frequency is set as once daily, and administration is preferably taken as a single dose in the morning. The daily dose is subject to titration, meaning it is officially adjusted based on the response obtained, ranging from one sachet every other day up to the 20 g maximum per day, as described in official labeling.


Population-Specific Use and Duration

For children 8 years and older, the dosing regimen is the same as the adult range (10 g to 20 g daily). However, the duration of use for this pediatric group is officially restricted and should not exceed 3 months. For younger children (6 months to under 8 years), standard guidelines prescribe lower, age-dependent doses utilizing the 4 g sachet strength. The treatment is classified as a temporary adjuvant measure and should be stopped gradually once a desired effect is achieved.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Paxabel (Macrogol 4000)


Evidence for Use in Chronic Functional Constipation

The majority of research on Macrogol 4000 has explored how symptoms change over time in patients dealing with chronic functional constipation, a condition characterized by fluctuating or episodic manifestations. The evidence landscape includes high-quality, intermediate-term Randomized Controlled Trials (RCTs) that examined Macrogol 4000 versus placebo and other agents such as lactulose. These studies were applied in studies examining patient-reported experiences related to the difficulty of elimination, including outcomes related to physical discomfort and measurements of bowel movement frequency.

Findings describe patterns observed in the studies where Macrogol 4000 treatment groups were monitored for measurements of stool consistency and frequency of bowel movements compared to placebo groups. Comparative research has explored how outcomes for Macrogol-based treatments compared to other agents, such as lactulose, in both adult and pediatric cohorts. This evidence contributes to understanding symptom patterns over the short-term and intermediate-term periods, which typically ranged up to 12 weeks.

Despite the volume of research, certain limitations exist. Certain research limitation frames apply, as comparative evidence is lacking in some areas. For instance, there are few blinded, high-quality RCTs directly comparing Macrogol 4000 to the full range of alternative laxatives. Furthermore, the results apply only to the populations studied, and while a large volume of research exists for this core use, long-term effects are not fully established beyond the 6-to-12-month duration studied in open-label maintenance research.


Evidence for Acute Treatment of Fecal Impaction

Research also explored the use of Macrogol 4000 in the acute setting of conditions associated with acute or disruptive episodes, specifically fecal impaction—a blockage of hard stool in the rectum or colon. This evidence research has explored the feasibility and observable effects of Macrogol 4000 versus other protocols, such as enemas or alternative osmotic agents. Studies in this context were often relevant in trials assessing short-term or episodic symptom patterns, with the primary focus on whether the impaction could be successfully cleared.

The research describes that Macrogol 4000 treatment was observed in some studies during the acute management of fecal impaction in the observed cohorts. These findings describe patterns observed in the studies related to the time it takes for the impaction to clear.

However, research in this area is limited. Sample sizes were modest in many impaction-specific RCTs, and the evidence base is derived predominantly from pediatric populations. As such, data for certain groups remain insufficient, particularly concerning large, dedicated studies for the acute treatment of fecal impaction in the general adult population.


Long-Term Study Duration and Follow-up Data

Studies have monitored the use of Macrogol 4000 over longer follow-up durations, extending up to 6 to 12 months in some open-label, non-comparative settings. This research contributes to understanding symptom patterns and stability during maintenance periods following initial symptom management. These studies monitored measurements of bowel function and certain physiological indicators, such as electrolyte levels, over time.

While these open-label studies offer evidence derived from settings with varying symptom burdens, there is limited information for long-term outcomes that are fully characterized by high-quality, blinded data extending past one year. Long-term effects are not fully established because the most rigorous, placebo-controlled trials typically have follow-up durations that were limited to a few weeks or months.


Research Evidence in Specific Patient Groups

Macrogol 4000 was evaluated in a variety of patient populations, particularly in the pediatric population. Extensive research has focused on functional constipation in children, from infants (generally ge 6 months of age) through adolescence, where it was studied for managing both chronic symptoms and acute fecal impaction. This evidence contributes to the broader evidence landscape of how patients reported their experience across different developmental stages.

Research has also explored its use in older adults with chronic constipation, and Macrogol 4000 was observed in this population in observational settings evaluating daily-life functioning. However, data for certain groups remain insufficient. This includes individuals with complex comorbidities or neurogenic conditions, where evidence is often drawn from smaller, more specialized studies.


Key Limitations and Areas of Scientific Uncertainty

The research on Macrogol 4000, while substantial, includes several recognized limitations. Comparative evidence is lacking for certain head-to-head comparisons against all major alternative laxatives. Furthermore, evidence quality varies across studies, particularly in specialized populations or in the management of fecal impaction.

The primary uncertainty is that long-term effects are not fully established beyond the intermediate follow-up periods seen in most high-quality trials. This means that while the studies help show what has been observed so far regarding short-term changes, the certainty remains low for outcomes sustained over several years. Research remains focused on defining patterns of use and long-term consequences.

Key Studies & References

  1. Macrogol (polyethylene glycol) 4000 without electrolytes in the symptomatic treatment of chronic constipation: a profile of its use
  2. National clinical constipation pathway for primary care for children - NHS England (Based on NICE guidance)
  3. Public Assessment Report Scientific discussion Clensia, powder for oral solution (Macrogol 4000, anhydrous sodium sulphate - Geneesmiddeleninformatiebank (Regulatory context for Macrogol 4000 combinations)

Frequently Asked Questions (FAQ)

Common questions about Paxabel (FAQ)

Q: Are there any specific foods or drinks that should be avoided when using Paxabel?

A: Official product information indicates that this medicine can be taken either with or without food. However, a specific caution is noted for patients using starch-based food thickeners for swallowing difficulties. Macrogol may cause these thickened liquids to liquefy, which presents a safety concern.

Q: Is it normal to feel a change in my body a few days after starting Paxabel?

A: According to official product information, the expected therapeutic effect typically manifests within 24 to 48 hours following the first administration. In addition to the primary effect, common and temporary changes noted in early use include minor gastrointestinal symptoms such as abdominal pain and bloating.

Q: Does Paxabel interact with common pain relievers like ibuprofen or acetaminophen?

A: Regulatory documents advise a general timing separation for Paxabel and all other orally administered medicines. Regulatory guidance suggests a time separation, advising that other oral medicines are generally not administered for one hour before, during, and one hour after Paxabel.

Q: What happens if I stop taking Paxabel suddenly?

A: Official guidelines recommend that, as a temporary treatment, its use be stopped gradually once a desired effect is achieved. The product information does not detail the consequences of abrupt discontinuation.

Q: Is it necessary to drink extra water while taking Paxabel?

A: The medicine's mechanism of action relies entirely on its dissolution in an aqueous medium and its ability to bind water in the gut. While not mandating extra water, official documents advise caution regarding water and electrolyte balance, particularly since excessive dosage can lead to fluid loss and diarrhea.

Q: I have another chronic condition; does official information address using Paxabel with other chronic illnesses?

A: Regulatory documentation indicates the importance of ruling out an underlying cause, such as an organic disorder, before treatment is initiated. If symptoms persist despite associated treatment, official information suggests that a pre-existing disease should be considered for further investigation.

Q: What are the common misunderstandings about how to correctly use Paxabel?

A: Official administration guidelines state that the powder contents are to be fully dissolved in water just before consumption, and are not to be taken dry. The product information also advises the one-hour timing separation from other oral medicines.

Q: Are the listed side effects for Paxabel different for children compared to adults?

A: Yes, there are some differences described in the official safety information. For example, faecal incontinence is listed as an uncommon adverse effect reported only in adults. Otherwise, the most common reported undesirable effects in children's clinical trials were minor and transient gastrointestinal disorders.

Q: What is the official instruction if a patient takes too much?

A: Official documents state that if an excessive dose is administered, the resulting diarrhea is typically relieved by temporary suspension of the medicine or reduction of the dosage. If diarrhea is severe and prolonged, excessive fluid loss may occur, which could require the correction of electrolyte disorders.

Q: If I miss a dose of Paxabel, what is the best thing to do?

A: Official patient information states that a forgotten dose is generally administered as soon as it is remembered, with the next dose taken at the usual time. It is also explicitly advised that a double dose is not to be taken to compensate for the missed one.

Q: Can Paxabel be split or crushed to make it easier to swallow?

A: The medicine is not supplied in a tablet form that can be crushed or split. It is supplied as a powder for oral solution which is required to be fully dissolved in a specified amount of water just prior to consumption.

Q: Does Paxabel need to be taken with food, or can it be taken on an empty stomach?

A: Official product information states that this medicine may be taken with or without food. This means the timing of administration relative to meals does not impact the medicine's core function.

Q: Can I use Paxabel if I am already taking herbal supplements?

A: Official guides recommend that because complementary medicines, herbal remedies, and supplements are not regulated or tested in the same way as prescription medicines, their use is disclosed to a doctor or pharmacist.

Q: What are the signs that Paxabel is not working for me?

A: Official documents state that if symptoms persist despite the use of the medicine and associated dietary measures, the patient may require a full clinical evaluation. This is to determine whether a pre-existing disease should be suspected and addressed.

Q: Can Paxabel cause fatigue or drowsiness?

A: Fatigue, increased tiredness, confusion, or dizziness are not primary side effects but are described in official information as potential signs of a more serious issue. These symptoms can be associated with an electrolyte imbalance or dehydration, which may occur in very rare cases of severe diarrhea or vomiting due to excessive dosage.

Q: How is the safety of Paxabel monitored after it has been approved?

A: Like all authorized medicines, the safety of Macrogol 4000 is continuously monitored after approval. This is achieved through the national and international pharmacovigilance systems, which include the ongoing collection, reporting, and evaluation of all suspected adverse reactions.

Q: Does Paxabel interact with blood thinners?

A: Regulatory documents advise a general timing separation for Paxabel and all other orally administered medicines. Regulatory guidance suggests a time separation, advising that other oral medicines are generally not administered for one hour before, during, and one hour after Paxabel.

How should Paxabel be stored and disposed of?

Storage and Disposal Requirements for Paxabel

The storage of Paxabel (macrogol 4000) powder for oral solution is divided based on its state of preparation, according to official regulatory labeling.

Storage Conditions

Item Requirement
Unopened Powder Must not be stored above 25 C and must be kept in the original sachet and carton.
Prepared Solution Must be stored in the refrigerator (2 C to 8 C) and used within 24 hours.

The medicine must, at all times, be kept out of the sight and reach of children to comply with mandated safety instructions.

Disposal

Unused or expired Paxabel must not be discarded through household waste or wastewater systems. Disposal must follow the instructions provided by a pharmacist or the local pharmaceutical waste scheme to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Paxabel found in:

A-Z Index: